c-Jun N-terminal kinase phosphorylates peroxisome proliferator- activated receptor-γ1 and negatively regulates its transcriptional activity

Endocrinology

Volumn 140, Issue 1, 1999, Pages 392-397

  Camp, Heidi S ^a   Tafuri, Sherrie R ^a   Leff, Todd ^a,b,c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Department of Cell Biology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; INSULIN RESISTANCE; LIGAND BINDING; LIPID METABOLISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0032894240     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.1.6457     Document Type: Article

References (45)

1. 1. Issemann I, Green S 1990 Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650
2. 2. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812
3. 3. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM 1995 A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83:813-819
4. 4. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W 1993 Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 90:2160-2164
5. 5. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W 1992 Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68:879-887
6. 6. Forman BM, Chen J, Evans RM 1996 The peroxisome proliferator-activated receptors: ligands and activators. Ann NY Acad Sci 804:266-275
7. 7. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA 1994 Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135:798-800
8. 8. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM 1994 mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234
9. 9. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956
10. 10. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM 1996 The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668
11. 11. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Patorniti Jr JR, Heyman RA 1997 Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386:407-410
12. 12. Saltiel AR, Olefsky JM 1996 Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669
13. 13. Camp HS, Tafuri SR 1997 Regulation of peroxisome proliferator-activated receptor γ activity by mitogen-activated protein kinase. J Biol Chem 272:10811-10816
14. 14. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK 1997 Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272:5128-5132
15. 15. Hu E, Kim JB, Sarraf P, Spiegelman BM 1996 Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 274:2100-2103
16. 16. Davis RJ 1994 MAPKs: new JNK expands the group. Trends Biochem Sci 19:470-473
17. 17. Whitmarsh AJ, Davis RJ 1996 Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74:589-607
18. 18. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ 1994 JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037
19. 19. Kallunki T, Su B, Tsigelny I, Sluss HK, Derijard B, Moore G, Davis R, Karin M 1994 JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev 8:2996-3007
20. 20. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, Woodgett JR 1994 The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369:156-160
21. 21. Han J, Lee JD, Bibbs L, Ulevitch RJ 1994 A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265:808-811
22. 22. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatler SW 1994 A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746
23. 23. Zhou G, Bao ZQ, Dixon JE 1995 Components of a new human protein kinase signal transduction pathway. J Biol Chem 270:12665-12669
24. 24. Graves RA, Tontonoz P, Spiegelman BM 1992 Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression [published erratum appears in Mol Cell Biol 1992 Jul;12(7):3313]. Mol Cell Biol 12:1202-1208
25. 25 Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ 1995 Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms [published erratum appears in Science 1995 Jul 7;269(5220):17]. Science 267:682-685
26. 26. Sanchez I, Hughes RT, Mayer BJ, Yee K, Woodgett JR, Avruch J, Kyriakis JM, Zon LI 1994 Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372:794-798
27. 27. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ 1995 Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270:7420-7426
28. 28. Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR, Templeton DJ 1994 Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372:798-800
29. 29. Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J 1996 Characterization of the structure and function of a new mitogen-activated protein kinase (p38β). J Biol Chem 271:17920-17926
30. 30. Kramer RM, Roberts EF, Um SL, Borsch-Haubold AG, Watson SP, Fisher MJ, Jakubowski JA 1996 p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 271:27723-27729
31. 31. Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C, Mercurio F, Johnson GL, Karin M 1995 Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268:286-290
32. 32. Blank JL, Gerwins P, Elliott EM, Sather S, Johnson GL 1996 Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3. regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase. J Biol Chem 271:5361-5368
33. 33. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL, Karin M 1994 Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266:1719-1723
34. 34. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM 1992 Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203
35. 35. Gille H, Sharrocks AD, Shaw PE 1992 Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 358:414-417
36. 36. Cavigelli M, Dolfi F, Claret FX, Karin M 1995 Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J 14:5957-5964
37. 37. Whitmarsh AJ, Yang SH, Su MS, Sharrocks AD, Davis RJ 1997 Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol Cell Biol 17:2360-2371
38. 38. Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ 1997 Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386:296-299
39. 39. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM 1995 Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95:2409-2415
40. 40. Pfeiffer A, Janott J, Mohlig M, Ristow M, Rochlitz H, Busch K, Schatz H, Schifferdecker E 1997 Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res 29:111-114
41. 41. Arner P 1996 Obesity and insulin resistance in Swedish subjects. Diabetes Med 13:S85-S86
42. 42. Hotamisligil GS, Shargill NS, Spiegelman BM 1993 Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87-91
43. 43. Lang CH, Dobrescu C, Bagby GJ 1992 Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130:43-52
44. 44. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM 1996 IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science 271:665-668
45. 45. Stephens JM, Lee J, Pilch PF 1997 Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 272:971-976